



CANTOR FITZGERALD VIRTUAL GLOBAL HEALTHCARE CONFERENCE 2021

Anthony Fernando, President & CEO

Shameze Rampertab, EVP & CFO

September 28, 2021

Forward Looking Statements

This presentation includes statements relating to the Senhance Surgical System's market development and a general corporate update. These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, whether the market development activities related to the Senhance Surgical System will be successful, the pace of adoption of our products by surgeons, the success and market opportunity of our products, the impact on the ongoing pandemic on our business and our customers, the effect on our business on existing and new regulatory requirements and other economic and competitive factors and whether we will be able to execute upon our corporate objectives. For a discussion of the risks and uncertainties associated with the Company's business, please review our filings with the Securities and Exchange Commission (SEC). You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this presentation and speak only as of the origination date of this presentation. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.





We believe in digitizing the interface between the surgeon and patient to pioneer a new era of **Performance-Guided Surgery** by unlocking the Clinical Intelligence to enable consistently superior outcomes and a new standard of surgery.

Asensus Surgical (NYSE American: ASXC)

Early-Commercial Stage Company Ushering In A New Era Of Minimally Invasive Surgery



Global
Regulatory
Approvals



Global
Training Centers



100+
Active Surgeon
Users



Active
Clinical Sites in
US, EU & Asia



5,000+
Surgeries
Performed



Compelling
Per Procedure
Economics



1st
eye-sensing camera control
haptic feedback
3 mm robotic instruments
augmented intelligence and machine vision
real-time surgical image analytics
pediatrics with robotic 3 mm




Strong
Talented Global
Team




Integrated
Remote
Mentoring

Global Market Trends in Surgical Robotics



Worldwide Robotic Penetration Rate is < 5%, Today



SURGICAL ROBOTICS IS A LARGE AND FAST-GROWING MARKET AND CONVERTING LAPAROSCOPIC SURGERY IS A GREENFIELD OPPORTUNITY

Current Robotics Market

Open Surgery
37mm
procedures



Current
Robotic Penetration
< 5%

Digital Laparoscopy

Laparoscopic Surgery
16mm
procedures



Greenfield
Opportunity for
Senhance

We Are Uniquely Focused on Laparoscopy

An Opportunity And Need To Add To The Ways Surgical Robotics Creates Value

Global Soft Tissue Abdominal Surgery Market

Laparoscopy: ~16 million

Applicable Technology

Digital Laparoscopy (multi-port)

Industry Participants



Surgical Technique

Laparoscopy

Fully Reusable

- Low \$ / procedure

Instruments

5mm & 3mm

- Advances MIS, broadens applicability

Articulating

- Enabling where needed

Advanced Technology

Intelligent Capabilities

- Evolving capabilities of surgeons

Open: ~37 million

Robotic Assisted Surgery (multi-port)



Medtronic



Open Surgery / Hybrid MIS

Limited / Single Use

8mm & 5mm

Wristed

Not Available

Senhance is the only platform able to address the conversion of laparoscopy by leveraging standard laparoscopic tools, digital information and decision support tools

Competitors are following the Da Vinci model and focusing on open surgery conversion

Senhance System Addresses Key Challenges Facing Hospitals and Laparoscopic Surgeons

Building The Bridge From Laparoscopy To Robotics



A **digital fulcrum** sets a dynamic virtual pivot point that helps potentially minimize the incision trauma

Standard reusable instruments keep costs similar to traditional laparoscopic instruments

Digital laparoscopy maintains familiar motion, ancillary tools, and techniques

The **3DHD visualization** provides the surgeon with additional intelligence regarding depth and spatial relation of organs

Eye-tracking camera control where the system can sense the surgeon's eye activity, allowing camera control

Open-platform architecture allows use and integration of existing OR technologies to maximize benefit from capital investments and support surgeon preference

Haptic sensing of the platform heightens the surgeon sensing of pressure/ tension through alerts if pressure threshold is reached for an added layer of security not currently available elsewhere

Allows the surgeon to be seated in an **ergonomically comfortable position** throughout the procedure


























Intelligent Surgical Unit™
Brings AI and Machine Learning capabilities to surgery



Senhance Connect
On-Demand, 2-way communication enabling remote mentoring

Robust Global Applicability

High Volume Procedural Approvals Widely Available To Address Significant Markets

				
	United States <i>FDA Approved</i>	European Union <i>CE Marked</i>	Japan <i>PMDA Approved</i>	Rest of World <i>Russia, Taiwan, Others</i>
Senhance System Surgical				
Procedural Indications for Use				
General				
GYN				
Thoracic*				
Pediatric				
Urology				
Addressable Market <i>(# of annual procedures)</i>	16 million			

*Non-cardiac, upper abdominal procedures

Digitizing Laparoscopic Instrumentation

Broad Instrumentation Add Unique Advantages For Surgeons And Patients



Core Laparoscopic



Ultrasonic



3mm



Articulating



*Developed broad instrument portfolio with **70+** instruments in the catalog*

*New standard in minimally invasive robotic surgery with **3mm** instruments*

*Reusable instruments enable **compelling per procedure economics***

Our Path To Market Leadership

Delivering A New Era In Digital Surgery

- 1 Educate surgeons on the benefits of Senhance
- 2 Grow global installed base
- 3 Increase global procedure volume
- 4 Expand the portfolio
- 5 Continue the technological advancement of Senhance

1 Educating Surgeons On The Benefits Of Senhance

Grow Compelling Set of Data to Demonstrate Clinical and Economic Value

60+
peer review
articles to date

Focused on the following data:

- Health economics
 - Cost per procedure
 - Procedure times/workflow
- Usability across specialties
- Clinical outcomes

The TransEnterix European Patient Registry for Robotic-Assisted Laparoscopic Procedures in Urology, Abdominal, Thoracic, and Gynecologic Surgery ("TRUST")

Dietmar Stephan¹, Ibrahim
Affiliations + expand
PMID: 33513657 DOI: 10.1111

Abstract

Introduction: Robotic surgery with the da Vinci System (Intuitive Surgical) has been a monopoly for years after its introduction in 2000 in Morrisville, North Carolina. The system is designed to assist surgeons with the Senhance™ digital navigation system and is designed to assist surgeons with the Senhance™ digital navigation system and is designed to assist surgeons with the Senhance™ digital navigation system.

Materials and methods: A retrospective analysis of 100 cases of laparoscopic local gastrectomy for gastrointestinal stromal tumor (GIST) performed with the Senhance™ digital navigation system and is designed to assist surgeons with the Senhance™ digital navigation system.

First experience using the Senhance surgical system in laparoscopic local gastrectomy for gastrointestinal stromal tumor

Hirofumi Sugita¹, Shinichi Sakuramoto², Junya Aoyama³, Sunao Ito⁴, Shuichi Oya⁵, Kenji Watanabe⁶, Naoto Fujiwara⁷, Hiroko Kondo⁸, Yutaka Miyawaki⁹, Yasumitsu Hirano¹⁰, Hiroshi Sato¹¹, Shigeki Yamaguchi¹², Isamu Koyama¹³

Affiliations + expand
PMID: 33590962 DOI: 10.1111

Abstract

Various innovative robotic systems have been developed for minimally invasive surgery. Several reports have described the use of the Senhance™ digital navigation system in laparoscopic local gastrectomy for gastrointestinal stromal tumor (GIST).

Keywords: GIST; Senhance surgical system; laparoscopic local gastrectomy; gastrointestinal stromal tumor (GIST).

© 2021 Japan Society for Endoscopy

Senhance surgical system in benign hysterectomy: A real-world comparative assessment of case times and instrument costs versus da Vinci robotics and laparoscopic-assisted vaginal hysterectomy procedures

Herbert Coussons¹, Josh Feldstein², Steve McCarus³

Affiliations + expand
PMID: 33860631 DOI: 10.1002/rcs.2261

Abstract


Objectives: Comparison of retrospective, learning curve benign hysterectomy cost and case time data from Senhance total laparoscopic hysterectomy (TLH) cases with similar da Vinci robot cases and laparoscopic-assisted vaginal hysterectomy (LAVH) cases.

Methods: Instrument costs, console time, and case time analysis from six surgeons at four U.S. and European hospitals compared with retrospective, sequential da Vinci TLH and standard laparoscopic LAVH cases extracted from the CAVAnalytics database.

Results: Senhance Gyn surgeons in their learning curve when compared to da Vinci learning curve Gyn surgeons achieved lower median instrument costs (\$559 vs. \$1393, respectively; $p < 0.001$) with comparable console times (91.5 vs. 96 min, $p = 0.898$); Senhance and LAVH case costs were comparable (\$559 vs. \$498, $p = 0.336$).

International Journal of Medical Robotics (Apr 2021)

Senhance surgical system in benign hysterectomy: A real-world comparative assessment of case times and instrument costs versus da Vinci robotics and laparoscopic-assisted vaginal hysterectomy procedures




- Senhance per procedure costs were less than half of da Vinci
- Senhance per procedure costs were in line with laparoscopy
- Case times between Senhance and da Vinci were comparable

2

Growing Global Installed Base

Expanding Number of Systems Being Used Across Multiple Geographies

**28**

Active Installed
Units

6

Global Training
Centers

13

Foundational
Sites

- 10 systems added in 2020
- 10 – 12 systems expected to be added in 2021
- 3 placements YTD 2021

- 2 Training Centers added in the past year


- Foundational Sites expected to expand in 2021

3

Increasing Global Procedure Volumes

Senhance Demonstrating Strong Clinical Performance Across The Three Major Geographies


GLOBAL CLINICAL CASE VOLUME TREND



Year end Active Sites	6	18	28	38-40**
-----------------------	---	----	----	---------

Strong clinical case performance

2020/2021* CASE MIX



Adoption across multiple specialty areas, demonstrating broader applicability and adoption

4

Expanding The Portfolio

Broadening Applicability Through Regulatory And Instrument Expansion

1H'21

CE Marking:
Initial ISU™

FDA 510(k) clearance:
**Expanded General
Surgery Indication**

- Provided Senhance digital laparoscopy programs access to new Augmented Intelligence technology
- Brings initial Performance-Guided Surgery capabilities to European hospitals
- Expanded on-label applicability
- Can be utilized in 2.7 million annual procedures
- Key to future growth

2H'21

FDA 510(k) clearance:
**Articulating
Instruments**


FDA 510(k) clearance:
**Next Wave ISU
Features**

- Widens the clinical utility to a broader number of surgeons
- Initiating limited launch before full commercialization in FY22
- Next phase in progress towards Performance-Guided Surgery
- Provide advanced Machine Vision and Augmented Intelligence capabilities
- Only robotic platform to offer scene recognition and surgical image analytics

5 Continue The Technological Advancement Of Senhance

Focused Investment To Deliver The Future Of Surgery

Senhance



Robust Digital Laparoscopy platform built on the fundamentals of MIS

Intelligent Surgical Unit™ (ISU™)




Digital Platform capable of machine vision and augmented intelligence to enable real-time surgical analytics

Performance-Guided Surgery




Clinical Intelligence to unlock superior outcomes with surgery

Performance-Guided Surgery




The Surgical Assurance Framework

UNLOCKING CLINICAL INTELLIGENCE




ISU: The First Machine Vision System In Robotic Surgery

Laying The Foundation For Digitizing Surgery → Enable Performance-Guided Surgery



Vision Based
Real-Time 3D
Point to Point
Measurement



Real-Time Defect
Identification and
Sizing

Senhance Connect


Mobile In-OR Surgeon Communication System



- Connects expert Senhance Surgeons across the Globe
- Streams multiple camera views and the endoscopic view simultaneously
- Allows 2-way screen sharing and annotation

Our Path to Market Leadership

Senhance



Robust Digital Laparoscopy platform built on the fundamentals of MIS

Intelligent Surgical Unit™ (ISU™)



Digital Platform capable of machine vision and augmented intelligence to enable real-time surgical analytics

Performance-Guided Surgery



Clinical Intelligence to unlock superior outcomes with surgery

Global organizational footprint and installed base

Continued focus and targeted investments that drive innovation to create the future of surgery

Surgery Reimagined

Performance-Guided Surgery – next
level technology that completely
changes the idea of what's possible.